OQROGet OQRO Pro
Insider trade

Merck (MRK)Officer sold ~$720K

David Michael Williams, Officer at Merck, sold ~$720K of Merck shares.

~$720K
Approx. value · 8,614 sh @ $83.59
25K
Holds after · shares reported
Traded
Nov 3, 2025
Filed
Nov 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 29, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  2. Mar 19, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  3. Aug 4, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  4. Aug 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  5. Aug 14, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  6. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
  7. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
  8. Sep 23, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  9. Oct 15, 2025FDAFDA drug approval: Bla761495
  10. Oct 24, 2025FDAFDA drug approval: Winrevair
  11. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  12. Nov 3, 2025 · this disclosureInsiderOfficer sold ~$720K of MRK shares in the open market

What came next

  1. Nov 10, 2025InsiderOfficer sold ~$616K of MRK shares in the open market
  2. Nov 13, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  3. Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  4. Nov 21, 2025FDAFDA drug approval: Keytruda
  5. Nov 21, 2025FDAFDA drug approval: Keytruda Qlex
  6. Dec 12, 2025FDARecall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured…
  7. Dec 12, 2025FDARecall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway…
  8. Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  9. Dec 19, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  10. Jan 13, 2026Federal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date
  11. Jan 27, 2026FDAFDA drug approval: Noxafil
  12. Jan 27, 2026FDAFDA drug approval: Noxafil
  13. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  14. Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
  15. Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
  16. Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
  17. Feb 9, 2026Insider · 2 peopleInsiders: 4 sales (~$15.7M)
  18. Feb 10, 2026FDAFDA drug approval: Keytruda
  19. Feb 10, 2026FDAFDA drug approval: Keytruda Qlex
  20. Feb 10, 2026InsiderOfficer sold ~$1.2M of MRK shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 123 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by David Michael Williams, EVP,Chief Info&Digital Officer

The full history of David Michael Williams, EVP,Chief Info&Digital Officer is on the profile page.

How this filing works

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data